United States-based Celgene has met its co-primary endpoint of progression-free survival in the phase III IMpassion130 study, which was sponsored by Roche, it was reported yesterday.
This is the first phase III study to showcase a statistically significant progression-free survival improvement in first-line metastatic or unresectable locally advanced triple negative breast cancer (TNBC), a type of breast cancer with high unmet need.
The study enrolled 902 people who were randomised equally (1:1). Results indicated that the investigational combination of TECENTRIQ (atezolizumab) and ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) compared to ABRAXANE monotherapy, as an initial (first-line) treatment, significantly decreased the risk of disease worsening or death in patients with metastatic or unresectable locally advanced TNBC in the intention-to-treat and PD-L1 positive populations.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886